U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
Trump-Iran Tensions Keep Oil Prices Elevated Amid Hormuz Supply Fears 
Trump DOJ Challenges Colorado’s Large-Capacity Magazine Ban in Second Amendment Lawsuit 
Is dark chocolate healthier than milk chocolate? 2 dietitians explain 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
Oil Prices Rise as Dollar Gains Ahead of Key U.S. Inflation Data 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
US Inflation Expected to Rise Again in April as Fed Signals Higher Interest Rates 
Sinaloa Governor Ruben Rocha Denies U.S. Cartel Allegations, Calls Charges Political 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
U.S. Army Soldier Charged in $400K Insider Betting Scheme on Maduro Capture 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth 
Bristol Myers Squibb has sued AstraZeneca for its antibody-based cancer treatment Imjudo, which it says infringes its patents for its drug Yervoy
According to Bristol Myer, Imjudo fights cancer in the same way as Yervoy.
Bristol Myers has previously sued AstraZeneca for patent infringement over the latter’s other cancer drug, Imfinzi.
AstraZeneca said it is aware of the complaint and will respond to it "at the appropriate time."
The FDA has also approved the immunotherapy Yervoy for the treatment of kidney, lung, colorectal, and other cancers. The FDA initially approved Yervoy in 2011 to treat melanoma.
In 2021, Bristol Myers sold over $2 billion worth of Yervoy.
AstraZeneca’s Imjudo was given FDA approval last year to be used in conjunction with Imfinzi to treat liver and lung cancer.
In the second lawsuit, Bristol Myers claimed that AstraZeneca had violated two patents on the use of antibodies to treat cancer and strengthen a patient's immune system.
Bristol Myers insists that AstraZeneca was aware of the patents, being on notice due to licensing discussions and the Imfinzi lawsuit.
The lawsuit seeks an unspecified amount of money for damages.
